Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

[1]  N. Snowise,et al.  Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial. , 2012, Respiratory medicine.

[2]  C. Crim,et al.  The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. , 2012, Chest.

[3]  A. Woodcock,et al.  Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. , 2012, Respiratory medicine.

[4]  A. Woodcock,et al.  24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids , 2012, European Respiratory Journal.

[5]  J. Lötvall,et al.  Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial , 2012, BMJ Open.

[6]  S. Rennard,et al.  Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease , 2008, Drugs.

[7]  A. Woodcock,et al.  Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial , 2011, Thorax.

[8]  K. Biggadike.  Fluticasone furoate/fluticasone propionate – different drugs with different properties , 2011, The clinical respiratory journal.

[9]  R. Sturton,et al.  Pharmacological Characterisation Of GW642444, A Long-acting ²2-agonist (LABA) With Rapid Onset And Long Duration, On Isolated Large And Small Human Airways , 2010, ATS 2010.

[10]  M. Dubinsky,et al.  Effect of medication dosing frequency on adherence in chronic diseases. , 2009, The American journal of managed care.

[11]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[12]  S. Rennard,et al.  Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. , 2008, Drugs.

[13]  S. Farrow,et al.  Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[14]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[15]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[16]  K. Lohr,et al.  Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes , 2006, The Annals of Family Medicine.

[17]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[18]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.

[19]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[20]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[21]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[22]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[23]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[24]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[25]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[26]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[27]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[28]  C K Wells,et al.  Evaluation of clinical methods for rating dyspnea. , 1988, Chest.